Viewing Study NCT04015232

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:58 PM
Ignite Modification Date: 2026-02-01 @ 6:45 AM
Study NCT ID: NCT04015232
Status: COMPLETED
Last Update Posted: 2019-10-04
First Post: 2019-07-08
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
Sponsor: Intas Pharmaceuticals, Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Immunogenicity View
None Healthy Volunteers View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pegfilgrastim View
None Biosimilar View
None Immunogenicity View
None Pharmacokinetics View
None Pharmacodynamics View
None Safety View
None Healthy Volunteers View